One of the European Parliament's key tasks is budgetary control: scrutinising if billions of taxpayers' money are spent in a proper and useful way. But in case of the EU's response to the Covid-19 pandemic and the tens of billions of euros the EU spends on purchasing vaccines from powerful pharmaceutical companies like Pfizer, it has renounced this task.
From recent letters seen by Corporate Europe Observatory, it seems the European Parl...
Enjoy access to all articles and 25 years of archives, comment and gift articles. Become a member for as low as €1,75 per week.
Already a member? LoginHans van Scharen researcher at Corporate Europe Observatory (CEO), the NGO which researches corporate lobbying in Brussels.
Hans van Scharen researcher at Corporate Europe Observatory (CEO), the NGO which researches corporate lobbying in Brussels.